CAR-T therapy toxicities: the importance of macrophages in their development and possible targets for their management
Abstract CAR-T cell therapies have risen to prominence over the last decade, and their indications are increasing with several products approved as early as second line in Large B Cell non-Hodgkin Lymphomas. Their major toxicities are the cytokine release syndrome (CRS) and the Immune-effector Cell...
Saved in:
| Main Authors: | Joseph Norton, Patrick Stiff |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-01-01
|
| Series: | Discover Oncology |
| Online Access: | https://doi.org/10.1007/s12672-025-01776-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Management strategies for CAR-T cell therapy-related toxicities: results from a survey in Greece
by: Eleni Gavriilaki, et al.
Published: (2025-05-01) -
From the mechanism of action to clinical management: A review of cardiovascular toxicity in adult treated with CAR-T therapy
by: Frank Nunes, et al.
Published: (2025-01-01) -
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells
by: Jiang Guoyun, et al.
Published: (2025-02-01) -
Gp350-targeted CAR-T therapy in EBV-positive Burkitt lymphoma: pre-clinical development of gp350 CAR-T
by: Jiajia Wang, et al.
Published: (2025-02-01) -
CAR-T therapy for endocrine neoplasms: novel targets and combination of therapies
by: Fang Wang, et al.
Published: (2025-02-01)